A Medical Device Daily

Temptime (Morris Plains, New Jersey) will donate its Vaccine Vial Monitors (VVMs) to the World Health Organization (WHO; Geneva) to monitor potential heat damage of H1N1 vaccines to be distributed by WHO to developing countries most in need.

"There are challenges related to the rapid distribution of the H1N1 vaccine during a pandemic situation, including the need to maintain proper temperature control of the vaccines from the manufacturer to the recipient. The use of vaccine vial monitors on donated H1N1 vaccine will allow health care providers to check the vaccine, prior to patient vaccination, to determine whether or not the vaccine has been exposed to excessive heat which might have rendered it ineffective," said WHO scientist, Umit Kartoglu, MD, DPH.

The donated VVMs (marketed under the name HEATmarker) are miniaturized, self adhesive devices that are affixed to temperature sensitive medical products to monitor storage and transport until time of use. The monitor progressively and irreversibly changes color as the vaccine is exposed to heat over time. As a VVM reaches its endpoint, an easy to read signal allows healthcare providers to determine if the vaccine has been exposed to potentially damaging heat and should not be used.

"When Temptime learned that WHO was receiving certain quantities of H1N1 vaccine for distribution to developing countries most in need, we quickly decided to support this global health initiative by donating VVMs to WHO for use on the donated vials of H1N1 vaccine" said Ted Prusik, PhD, after attending a WHO meeting.

In other agreements/contracts news:

• OSI Systems (Hawthorne, California) has been awarded a one-year $13.5 million Indefinite Delivery Indefinite Quantity (IDIQ) contract from the U.S. Defense Supply Center Philadelphia Medical Supplier Operations Directorate to provide patient monitoring systems, sub-systems, training and consumables. OSI Systems chairman/CEO, Deepak Chopra, said, "We are pleased to be working closely with the DSCP on this procurement. The award highlights our broad product portfolio with approximately 25 products named in the IDIQ not including the consumables. Products provided will be distributed nationally to all branches of the U.S. armed forces in addition to other U.S. government agencies."

• EMD Chemicals (Gibbstown, New Jersey), a supplier of assays, reagents and chemicals for the life science and drug discovery market, reported a research and commercial collaboration with MitoSciences (Eugene, Oregon), a developer of antibodies and immunoassays for measuring mitochondrial and metabolic function. The new collaboration allows for co-development of multiplex immunoassay products for the WideScreen BeadPlex assay platform for the detection and profiling of mitochondrial toxicity and activity. This enables EMD Chemicals to expand its already extensive offering in the multiplex biomarker, drug discovery and drug development markets. MitoSciences has granted EMD Chemicals exclusive rights to a large new offering of currently unlicensed monoclonal antibodies for monitoring mitochondrial toxicity and bioactivity. MitoSciences will work exclusively with EMD Chemicals to validate the new WideScreen assays for use in drug screening applications.

• Solos Endoscopy (Boston) has received additional purchase orders for its MammoView line of surgical endoscopy instruments from the National Cancer Institute (NCI), as well as the U.S. National Institute of Health (NIOH). "We are very pleased to continue supplying our MammoView surgical endoscopy instruments to the top cancer care and research organizations in the country. We believe, as the body of research expands, more and more surgeons will utilize our system, which will enable them to detect possible cancerous cells in its early stage and begin treatments immediately on their patients," said Bob Segersten, Solos president.